Prosecution Insights
Last updated: April 19, 2026

Examiner: COUGHLIN, MATTHEW P

Tech Center 1600 • Art Units: 1626

This examiner grants 71% of resolved cases

Performance Statistics

71.3%
Allow Rate
+11.3% vs TC avg
1032
Total Applications
+12.2%
Interview Lift
909
Avg Prosecution Days
Based on 984 resolved cases, 2023–2026

Rejection Statute Breakdown

1.7%
§101 Eligibility
20.4%
§102 Novelty
24.9%
§103 Obviousness
30.3%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18039188 COMPOUND, ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC APPARATUS Non-Final OA IDEMITSU KOSAN CO.,LTD.
18375697 COMPOSITIONS AND METHODS FOR TREATING OCULAR CHEMICAL BURNS Non-Final OA OHIO STATE INNOVATION FOUNDATION
17794962 BACTERIAL TOPOISOMERASE INHIBITORS DERIVED FROM ISOMANNIDE Final Rejection Ohio State Innovation Foundation
18455029 PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES Non-Final OA Hoffmann-La Roche Inc.
17976651 NOVEL IMIDAZOPYRAZINE DERIVATIVES Final Rejection Hoffmann-La Roche Inc.
18265754 METHOD FOR PREPARATION OF DEUTERATED ANTHRACENE COMPOUND, REACTION COMPOSITION, DEUTERATED ANTHRACENE COMPOUND, AND COMPOSITION Non-Final OA LG CHEM, LTD.
18123018 Circularly Recyclable Polymers Featuring Topochemically Elongated Carbon-Carbon Bonds Non-Final OA Purdue Research Foundation
18555112 COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CANCER Non-Final OA Yale University
18552715 COMPOSITION FOR AMELIORATING OR SUPPRESSING DECLINE OF KIDNEY FUNCTIONS Non-Final OA SUNTORY HOLDINGS LIMITED
18015746 MONOTERPENOID AND PHENYLPROPANOID CARBONATE ESTERS AND METHODS OF THEIR MAKING AND USE AS REPELLENTS Non-Final OA IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
17905455 AROMATIC COMPOUND, ORGANIC SEMICONDUCTOR LAYER AND ORGANIC THIN FILM TRANSISTOR Final Rejection TOSOH CORPORATION
18325264 PROCESS FOR PRODUCING FURFURAL FROM BIOMASS Non-Final OA UOP LLC
18626788 PROCESS FOR PREPARING SUBSTITUTED CYCLOHEXANE AMINO ACID ESTERS AND SPIROKETAL-SUBSTITUTED CYCLIC KETO-ENOLS Final Rejection Bayer Aktiengesellschaft
18279815 PYRIMIDINE OR PYRIDINE DERIVATIVES USEFUL AS HCN2 MODULATORS Non-Final OA King's College London
18259606 Metal Complexes and Methods for the Same Non-Final OA Colgate-Palmolive Company
18113206 TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES Non-Final OA Cornell University
18758924 Compositions And Methods Targeting G12 Signaling For Bronchodilator Therapy Non-Final OA Rutgers, The State University of New Jersey
18036095 PHENOTHIAZINE COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AGE-RELATED AND NEUROLOGICAL DISEASES Non-Final OA Icahn School of Medicine at Mount Sinai
17776870 A CONTINUOUS PROCESS FOR THE SYNTHESIS OF AZO DYES INVOLVING IN-SITU GENERATION OF DIAZONIUM SALTS Non-Final OA Council of Scientific and Industrial Research
18573510 NOVEL CRYSTALLINE FORM OF 1-(8-BROMOPYRIDO[2,3-E][1,2,4]TRIAZOLO[4,3-A]PYRAZIN-4-YL)-N-METHYLAZETIDIN-3-AMINE HEMISUCCINATE Non-Final OA JW PHARMACEUTICAL CORPORATION
18569867 BENZOXAZINONE DERIVATIVES Non-Final OA MEDSHINE DISCOVERY INC.
18519533 COMPOUNDS AND USES THEREOF Non-Final OA FOGHORN THERAPEUTICS INC.
18275929 GLOBODERA PALLIDA CONTROL AGENT Non-Final OA Nippon Soda Co., Ltd.
18122892 PROCESSES FOR THE PREPARATION OF SUBSTITUTED SPIROOXINDOLE DERIVATIVES Non-Final OA ENANTA PHARMACEUTICALS, INC.
17802827 COMPOUNDS AND METHODS FOR MODULATING SPLICING Final Rejection REMIX THERAPEUTICS INC.
18027005 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING Non-Final OA Neuropore Therapies, Inc.
17390064 CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE Final Rejection Hangzhou DAC Biotech Co., Ltd.
17926886 TREATMENT OF CORONAVIRUS Non-Final OA ENA Respiratory Pty Ltd
17593380 CAPTURE OF MICROVESICLES FOR DIAGNOSTIC PURPOSES Non-Final OA CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX
17190177 PROANGIOGENIC COMPOSITIONS AND METHODS OF USE Non-Final OA University of North Dakota

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month